Delivery Order SPE2DB24D9222-SPE2DB25FAZKR
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 5, 2025, for the supply of Xtandi 40 mg tablets (120-count packages). The contract, valued at $8,339.18 with an ultimate completion date of August 6, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, which is scheduled for completion by September 10, 2025, represents a tactical execution under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract ceiling value is $38,376.87, with an ultimate completion date of September 11, 2025. This delivery order carries no set-aside designation and represents a direct fulfillment order under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract utilizes a firm fixed-price structure with no set-aside designation and is scheduled for completion by August 12, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract, which carries no set-aside designation, is scheduled for completion by July 22, 2025, with performance at the vendor's Park Ridge location. This delivery order is issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 11, 2025, by the Defense Logistics Agency (DLA) for Xtandi 80 mg tablets (60-count packages) with a ceiling value of $12,508.77. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, was issued without a set-aside designation. The contract represents a discrete fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, valued at $4,169.59 for the supply of Xtandi 40 mg tablets (120 count) to the Defense Logistics Agency (DLA). This firm fixed-price delivery order, which must be completed by July 29, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $4,169.59 by the Defense Logistics Agency for the supply of Xtandi 80 mg tablets (60-count units). The award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- SPE2DB24D9222Indefinite Delivery Contract
- SPE2DB24D9222-SPE2DB25FAZKRDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The contract, valued at $8,339.18 with a completion date of September 12, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion vehicle that runs through November 2026 and authorizes the agency to issue firm fixed-price delivery orders for pharmaceutical products supporting military healthcare facilities nationwide. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, and this delivery order represents one of many pharmaceutical product acquisitions DMS Pharmaceutical Group fulfills for the Department of Defense healthcare system. The company's robust federal contract portfolio demonstrates its established role as a critical supplier in the federal pharmaceutical supply chain, consistently delivering branded and generic prescription drugs, biologics, and medical consumables to military medical facilities. As the primary funding source, the DLA leverages partnerships with qualified vendors like DMS Pharmaceutical Group to maintain cost-effective access to essential medications and medical supplies across the Defense healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/11/25 |